^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

NFKB1 overexpression

i
Other names: NFKB1, KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Entrez ID:
Related biomarkers:
7ms
Prostate cancer invasion is promoted by the miR-96-5p-induced NDRG1 deficiency through NF-κB regulation. (PubMed, Klin Onkol)
MiR-96-5p promotes the migration and invasion of PCa by targeting NDRG1 and regulating the NF-kB pathway.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MIR96 (MicroRNA 96) • NDRG1 (N-Myc Downstream Regulated 1) • NFKBIA (NFKB Inhibitor Alpha 2)
|
NFKB1 overexpression • NDRG1 overexpression
1year
Synthesis Folate-linked Chitosan-coated Quetiapine/BSA Nano-Carriers as the Efficient Targeted Anti-Cancer Drug Delivery System. (PubMed, Mol Biotechnol)
The efficient selective cytotoxic impact of FCQB-NCs can be due to the novel stepwise release mechanism of the FCQB-NCs based on the two-phase entrapment of QTP by BSA and chitosan molecules. Therefore, FCQB-NCs have the potential to be used as an efficient selective anti-breast cancer.
Journal
|
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
NFKB1 overexpression
2years
Genomic Aberrations Generate Fusion Gene FOXK2::TP63 and Activate NFKB1 in Cutaneous T-Cell Lymphoma. (PubMed, Biomedicines)
Finally, treatment of HH with NFkB inhibitor demonstrated a role for NFkB in supporting proliferation, while usage of inhibitor DAPT showed significant survival effects via the NOTCH pathway. Collectively, our data suggest that NFkB and/or NOTCH inhibitors may represent reasonable treatment options for subsets of CTCL patients.
Journal
|
MIR155 (MicroRNA 155) • IRF4 (Interferon regulatory factor 4) • IKZF2 (IKAROS family zinc finger 2) • TP63 (Tumor protein 63) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • NFKB2 (Nuclear Factor Kappa B Subunit 2)
|
NFKB1 overexpression • NFKB1 expression
over2years
Identify Bcl3 as a novel biomarker shared between severe asthma and lung cancer using next-generation RNA sequencing from archival FFPE tissue biopsies (ERS 2022)
Our findings indicate a Bcl3 a novel putative biomarker in pathogeneses of both severe asthma and lung cancer.
CD44 (CD44 Molecule) • STAT1 (Signal Transducer And Activator Of Transcription 1) • BCL3 (BCL3 Transcription Coactivator)
|
NFKB1 overexpression • BCL3 overexpression
almost4years
Journal
|
NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • MIR195 (MicroRNA 195)
|
NFKB1 overexpression • NFKB1 expression